Obatoclax (GX15-070), a small-molecule inhibitor of antiapoptotic Bcl-2 proteins, has been reported to trigger cell death via autophagy. However, the underlying molecular mechanisms have remained elusive. Here, we identify GX15-070-stimulated assembly of the necrosome on autophagosomal membranes as a key event that connects GX15-070-stimulated autophagy to necroptosis. GX15-070 predominately induces a non-apoptotic form of cell death in rhabdomyosarcoma cells, as evident by lack of typical apoptotic features such as DNA fragmentation or caspase activation and by insensitivity to the broad-range caspase inhibitor zVAD.fmk. Instead, GX15-070 triggers massive accumulation of autophagosomes, which are required for GX15-070-induced cell death, as blockade of autophagosome formation by silencing of Atg5 or Atg7 abolishes GX15-070-mediated cell death. Co-immunoprecipitation studies reveal that GX15-070 stimulates the interaction of Atg5, a constituent of autophagosomal membranes, with components of the necrosome such as FADD, RIP1 and RIP3. This GX15-070-induced assembly of the necrosome on autophagosomes occurs in a Atg5-dependent manner, as knockdown of Atg5 abrogates formation of this complex. RIP1 is necessary for GX15-070-induced cell death, as both genetic and pharmacological inhibition of RIP1 by shRNAmediated knockdown or by the RIP1 inhibitor necrostatin-1 blocks GX15-070-induced cell death. Similarly, RIP3 knockdown rescues GX15-070-mediated cell death and suppression of clonogenic survival. Interestingly, RIP1 or RIP3 silencing has no effect on GX15-070-stimulated autophagosome formation, underlining that RIP1 and RIP3 mediate cell death downstream of autophagy induction. Of note, GX15-070 significantly suppresses tumor growth in a RIP1-dependent manner in the chorioallantoic membrane model in vivo. In conclusion, GX15-070 triggers necroptosis by promoting the assembly of the necrosome on autophagosomes. These findings provide novel insights into the molecular mechanisms of GX15-070-induced non-apoptotic cell death.
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Obatoclax (GX15-070), a small-molecule inhibitor of antiapoptotic Bcl-2 proteins, has been reported to trigger cell death via autophagy. However, the underlying molecular mechanisms have remained elusive. Here, we identify GX15-070-stimulated assembly of the necrosome on autophagosomal membranes as a key event that connects GX15-070-stimulated autophagy to necroptosis. GX15-070 predominately induces a non-apoptotic form of cell death in rhabdomyosarcoma cells, as evident by lack of typical apoptotic features such as DNA fragmentation or caspase activation and by insensitivity to the broad-range caspase inhibitor zVAD.fmk. Instead, GX15-070 triggers massive accumulation of autophagosomes, which are required for GX15-070-induced cell death, as blockade of autophagosome formation by silencing of Atg5 or Atg7 abolishes GX15-070-mediated cell death. Co-immunoprecipitation studies reveal that GX15-070 stimulates the interaction of Atg5, a constituent of autophagosomal membranes, with components of the necrosome such as FADD, RIP1 and RIP3. This GX15-070-induced assembly of the necrosome on autophagosomes occurs in a Atg5-dependent manner, as knockdown of Atg5 abrogates formation of this complex. RIP1 is necessary for GX15-070-induced cell death, as both genetic and pharmacological inhibition of RIP1 by shRNAmediated knockdown or by the RIP1 inhibitor necrostatin-1 blocks GX15-070-induced cell death. Similarly, RIP3 knockdown rescues GX15-070-mediated cell death and suppression of clonogenic survival. Interestingly, RIP1 or RIP3 silencing has no effect on GX15-070-stimulated autophagosome formation, underlining that RIP1 and RIP3 mediate cell death downstream of autophagy induction. Of note, GX15-070 significantly suppresses tumor growth in a RIP1-dependent manner in the chorioallantoic membrane model in vivo. In conclusion, GX15-070 triggers necroptosis by promoting the assembly of the necrosome on autophagosomes. These findings provide novel insights into the molecular mechanisms of GX15-070-induced non-apoptotic cell death. Programmed cell death represents a basic cellular process that is frequently disturbed in human diseases. 1 There are several distinct forms of programmed cell death, including apoptosis, necroptosis and autophagic cell death. 2 Evasion of programmed cell death constitutes a hallmark of human cancers and may be caused by dysregulation of pro-and antiapoptotic signals. 3 For example, antiapoptotic proteins of the Bcl-2 family proteins are frequently overexpressed in human cancers. 4 As high expression levels of antiapoptotic Bcl-2 proteins can confer treatment resistance, small-molecule inhibitors have been developed to neutralize their cytoprotective functions. 5 GX15-070 is a small-molecule indole bipyrrole compound that antagonizes Bcl-2, Bcl-X L , Bcl-w and Mcl-1. 5 Although GX15-070 as single agent or in combination regimens is currently under clinical evaluation for the treatment of hematological malignancies and solid tumors, 6 the molecular mechanisms of its antitumor activity have still not been fully resolved. By neutralizing antiapoptotic Bcl-2 proteins, GX15-070 has been shown to engage the mitochondrial (intrinsic) pathways of apoptosis. [7] [8] [9] In addition to apoptosis, non-apoptotic cell death pathways, in particular autophagy, have been implicated in GX15-070-mediated cytotoxicity. [9] [10] [11] [12] [13] Macroautophagy (hereafter referred to as autophagy) is an evolutionarily conserved, ubiquitous and multi-step process by which cytosolic material is sequestered in a double-layered membrane, delivered to the lysosome for degradation and recycled to fuel cellular growth.
14 Autophagy starts with the formation of an isolation membrane also called phagophore that elongates, encapsulates cytoplasmatic cargo and seals to form the autophagosome.
14 Vesicle elongation and formation of the autophagosome are cooperatively mediated by two ubiquitin-like conjugation systems. The Atg12 conjugation system involves the covalent conjugation of Atg12 to Atg5, which then interacts with Atg16L to form the Atg5-Atg12-Atg16L complex. 15 In the second pathway, phosphatidylethanolamine is conjugated to LC3, one of the mammalian homologues of Atg8, which leads to the conversion of the soluble form of LC, that is, LC3-I, to the autophagic-vesicle-associated form LC3-II. 15 The autophagosome eventually fuses with the lysosome to generate the autophagolysosome where the cargo is broken down into its constituent components.
14 Autophagy is often engaged as part of a cellular stress reaction upon exposure to cytotoxic drugs and can exert dual functions in the regulation of either cell death or survival, likely in a context-dependent manner. 16 Although GX15-070 has been shown to engage autophagy, 9, 10, [17] [18] [19] possibly via the disruption of the Beclin1/Mcl-1 interaction, 10,11 the critical question whether or not GX15-070-stimulated autophagic activity promotes or inhibits cell death has been controversially discussed. On one side, GX15-070-induced autophagy has been linked to cell death, as genetic or pharmacological blockage of autophagy was found to inhibit cell death. [9] [10] [11] On the other side, inhibition of autophagy was described to enhance GX15-070-induced cell death, supporting a cytoprotective function of autophagy. 18 Besides this controversial discussion on the functional relevance of autophagy for GX15-070-triggered cytotoxicity, the molecular mechanisms of autophagic cell death upon treatment with GX15-070 have remained elusive.
Necroptosis (programmed necrosis) represents another regulated, caspase-independent mode of cell death. 2 The serine/threonine kinases receptor-interacting protein 1 (RIP1) and RIP3 are critical components of the necrosome, a cytosolic multiprotein complex that is required for necroptosis signaling.
20 RIP1 has been identified in a genome-wide screen as a key regulator of necroptosis 21 and its kinase activity was shown to be necessary for the induction of necroptosis by phosphorylating RIP3. 22 In addition to tumor necrosis factor a (TNFa)-mediated necroptotic cell death, 23 necroptosis can be initiated by several cellular stress stimuli, including DNA damage, ROS species and hypoxia. 23 Rhabdomyosarcoma (RMS) is the most frequent pediatric soft tissue sarcoma and can be classified into two major pathological subtypes, that is, embryonal RMS (ERMS) and alveolar RMS (ARMS). 24 ARMS frequently harbors reciprocal chromosomal translocations between chromosomes 1 or 2 and chromosome 13, resulting in chimeric fusion genes composed of PAX3 or PAX7 and FOXO1A. 25 Both PAX3 and PAX3/FKHR transcription factors were reported to stimulate Bcl-X L mRNA expression in RMS. 26 In addition, Mcl-1 was found to be frequently overexpressed in RMS, 27 supporting the notion that Bcl-2 proteins are dysregulated in RMS. 28 The prognosis for children with RMS is still poor irrespective of aggressive multimodal treatment protocols, 29 underscoring the need for innovative therapeutic approaches. In the present study, we used RMS as a model to investigate the molecular mechanisms of GX15-070-induced cytotoxicity.
Results

GX15
-070 induces non-apoptotic, caspase-independent cell death in RMS cells. Initially, we examined the expression levels of key pro-and antiapoptotic Bcl-2 proteins in several RMS cell lines, which represent ERMS (RD, TE671) and ARMS (RMS13, Rh30, Rh41). RMS cell lines expressed the antiapoptotic Bcl-2 proteins Bcl-2, Bcl-X L and Mcl-1, the multidomain proapoptotic Bcl-2 proteins Bax and Bak and the BH3-only proteins Bid, Bim and Noxa ( Figure 1a) .
Next, we investigated the responsiveness of RMS cell lines to GX15-070. Treatment with GX15-070 reduced cell viability in a dose-dependent manner in all RMS cell lines at nanomolar concentrations ( Figure 1b) . As TE671 and RMS13 cells turned out to be most responsive to GX15-070 and as they represent the two major subtypes of RMS, that is, ERMS and ARMS, we selected these two cell lines for further mechanistic studies. Kinetic analysis showed that GX15-070 decreased cell viability in a time-dependent manner ( Figure 1c) .
To investigate whether cells die via apoptosis, we analyzed DNA fragmentation, a characteristic feature of apoptotic cell death. We noticed that GX15-070 caused little DNA fragmentation under conditions where the majority of cells already lost their viability, for example, upon treatment with 200 nM GX15-070 for 48 h (Figures 1c and d) . By comparison, treatment with ABT-737, a small-molecule inhibitor of Bcl-2, Bcl-X L and Bcl-w that was used as a positive control to induce apoptosis, triggered loss of cell viability in parallel with massive DNA fragmentation (Supplementary Figure S1 ). In addition, GX15-070-treated cells displayed swollen cytoplasm but lacked typical apoptotic features such as plasma membrane blebbing and nuclear fragmentation, which were observed in ABT-737-treated cells (Supplementary Figure S2) , further pointing to a non-apoptotic mode of cell death by GX15-070.
To explore whether GX15-070-induced cell death depends on caspase activity, we examined the effect of the broadspectrum caspase inhibitor N-benzyloxycarbonyl-Val-AlaAsp-fluoromethylketone (zVAD.fmk). Of note, zVAD.fmk failed to block both loss of cell viability as well as DNA fragmentation upon treatment with GX15-070 ( Figures  2a and b) , whereas it almost completely rescued cell viability as well as DNA fragmentation in response to ABT-737 that was used as positive control for inducing apoptosis (Supplementary Figure S3) . Consistently, monitoring activation of the caspase cascade by western blot analysis revealed little cleavage of caspase-8, -9 or -3 by GX15-070, whereas ABT-737 triggered cleavage of caspases into active fragments (Figure 2c ). Furthermore, neither knockdown nor overexpression of Bcl-2 substantially altered GX15-070-induced cell death (Supplementary Figure S4) .
Furthermore, we examined whether GX15-070-induced cell death depends on autocrine/paracrine TNFa signaling using both a pharmacological and a genetic approach. Addition of the TNFa-blocking antibody Enbrel failed to rescue GX15-070-induced cell death, whereas Enbrel significantly protected against cell death following treatment with TNFa and IAP inhibitor 3 used as a positive control (Figures 2d and e) . Similarly, RNA interference-mediated knockdown of TNFR1 did not prevent GX15-070-induced cell death (Figures 2f-h) . Together, this set of experiments indicates that GX15-070 predominately induces a non-apoptotic, caspase-and TNFaindependent form of cell death.
GX15-070 induces autophagy. As autophagy has been implicated in caspase-independent cell death triggered by GX15-070, [9] [10] [11] [12] we next asked whether GX15-070 stimulates autophagy in RMS cells. Indeed, GX15-070 triggered GX15-070 triggers necroptosis via autophagy F Basit et al massive conversion of LC3-I to LC3-II (Figure 3a) . To distinguish whether this accumulation of autophagosomes is caused by increased production or, alternatively, by reduced clearance due to disruption of the autophagic flux, we examined GX15-070-stimulated autophagosome formation in the presence and absence of Bafilomycin A1 (BafA1). BafA1 is a specific inhibitor of the lysosomal proton pump that disrupts the autophagic flux by preventing the fusion of autophagosomes with lysosomes. 30 We detected increased LC3-II levels after cotreatment with GX15-070 and BafA1 compared with treatment with GX15-070 or BafA1 alone (Figure 3b ), suggesting that GX15-070 does not primarily disrupt the autophagic flux. In addition, we monitored the autophagic flux by using a tandem mCherry-GFP-tagged LC3 construct. As the GFP signal is acid-sensitive and the mCherry-tag is acid-insensitive, autophagosomes emit yellow fluorescence derived from both tags, while autophagolysosomes exhibit red fluorescence, as the green GFP-tag is degraded upon fusion of autophagosomes with lysosomes. We found that treatment with GX15-070 triggered the formation of red dots indicative of an ongoing autophagic flux where autophagosomes fuse with lysosomes ( Figure 3c ). By contrast, treatment with BafA1 increased the number of yellow dots consistent with the disruption of the autophagic flux by BafA1 (Figure 3c ). Cotreatment with GX15-070 and BafA1 yielded both red and (f-h) TE671 and RMS13 cells were transfected with control siRNA (siCtrl) or two distinct siRNA sequences against TNFR1 (siTNFR1#1, siTNFR1#2). Expression of TNFR1 was determined by western blotting (f) Cell viability was determined by MTT assay after treatment for 72 h with the indicated concentrations of GX15-070 (g) or with 100 ng/ml TNFa and 10 mM IAP inhibitor 3 (h) and is expressed as percentage of untreated controls. In panels a, b, d, e, g and h, data represent mean þ S.D. of three independent experiments performed in triplicate; **Po0.001
GX15-070 triggers necroptosis via autophagy F Basit et al yellow dots (Figure 3c ). These findings indicate that GX15-070 stimulates autophagy by increasing the production of autophagosomes rather than blocking the autophagic flux.
Atg5 and Atg7 are required for GX15-070-induced autophagy and cell death. As autophagy can exert either cytoprotective or cytotoxic functions depending on the context, we next asked whether autophagy inhibits or promotes GX15-070-mediated cell death. To address this question, we silenced Atg5 to block the induction of autophagy by GX15-070. Efficient knockdown of Atg5 protein by two distinct shRNA vectors was confirmed by western blot analysis compared with the control vector harboring a nonsilencing sequence (Figure 4a ). Silencing of Atg5 profoundly impaired the conversion of LC3-I to LC3-II upon treatment with GX15-070, demonstrating that it inhibits autophagosome formation (Figure 4b ). Importantly, Atg5 knockdown significantly rescued GX15-070-triggered loss of cell viability compared with cells harboring the control vector (Figure 4c ).
To further test the requirement of autophagy in GX15-070-induced cell death, we used a second approach to interfere with autophagosome formation by RNAi-mediated knockdown of Atg7. Control experiments showed that silencing of Atg7 caused efficient knockdown of Atg7 protein compared with a non-silencing control siRNA sequence (Figure 4d ) and markedly inhibited GX15-070-stimulated conversion of LC3-I to LC3-II (Figure 4e ). Similar to Atg5, also knockdown of Atg7 significantly reduced loss of cell viability upon GX15-070 treatment (Figure 4f ), thus confirming that induction of autophagy is required for GX15-070-stimulated cell death.
GX15-070 triggers the assembly of the necrosome on autophagosomes. Having established that autophagy is necessary for GX15-070-mediated cytotoxicity, we next aimed at understanding how the autophagic machinery is connected to cell death signaling pathways. To this end, we asked whether GX15-070-triggered formation of autophagosomal membranes may serve as a cytosolic signaling (Figure 4b) . Strikingly, the interaction of RIP1 with FADD and RIP3 was completely abolished in Atg5 knockdown cells (Figure 5b ), which were also severely impaired to produce autophagosomes (Figure 4b ). This indicates that Atg5-mediated formation of autophagosomes is required for the assembly of the RIP1-, RIP3-and FADD-containing necrosome complex during GX15-070-induced cell death.
RIP1 and RIP3 are required for GX15-070-induced cell death downstream of autophagosome formation. Based on our findings that GX15-070 triggers the formation of the necrosome on autophagosomal membranes (Figure 5a ), we then asked whether GX15-070 induces cell death by engaging necroptosis, a RIP1-and/or RIP3-dependent regulated necrosis. 2 To address this question, we used necrostatin-1 (Nec-1), a RIP1-specific inhibitor that has been reported to block necroptosis. 31 Of note, Nec-1 significantly rescued GX15-070-induced loss of cell viability (Figure 6a) , demonstrating that RIP1 kinase activity is required for GX15-070-triggered cell death.
In addition to this pharmacological approach, we also used a genetic strategy to selectively silence RIP1 in order to test the requirement of necroptosis in GX15-070-triggered cell death. Control experiments confirmed efficient, shRNAmediated knockdown of RIP1 protein (Figure 6b) . Importantly, RIP1 silencing significantly rescued GX15-070-induced loss of cell viability (Figure 6c ). To explore whether RIP1 knockdown has an impact also on long-term clonogenic survival in addition to supporting cell viability in short-term assays, we performed colony assays. Notably, RIP1 silencing significantly protected against GX15-070-induced suppression of clonogenic survival (Figure 6d ).
To investigate whether RIP1 is required for the formation of the Atg5/FADD/RIP1/RIP3 complex, we examined complex formation in RIP1 knockdown and control cells by immunoprecipitating FADD. Importantly, the interaction of Atg5 and FADD with RIP3 was completely abolished in RIP1 knockdown cells (Figure 6e ). This indicates that RIP1 is required for the formation of the necrosome complex on autophagosomes during GX15-070-induced cell death.
To further provide evidence that the induction of autophagosomes occurs before the assembly of the necrosome, we analyzed LC3 conversion in RIP1 knockdown and control cells. Interestingly, knockdown of RIP1 did not alter the conversion of LC3-I to LC3-II upon GX15-070 treatment (Figure 6f ), thus placing GX15-070-stimulated autophagosome formation upstream of RIP1.
In addition to silencing RIP1, we also knocked down RIP3 to test the requirement of the necrosome for GX15-070-triggered cell death. Efficient silencing of RIP3 by shRNA vectors was confirmed by western blot analysis (Figure 7a) . Importantly, RIP3 knockdown significantly inhibited loss of cell viability and considerably increased colony formation upon GX15-070 treatment compared with control vector cells (Figures 7b and c) . Similar to RIP1, knockdown of RIP3 did not prevent GX15-070-stimulated conversion of LC3-I to LC3-II (Figure 7d ).
This set of experiments demonstrates that both RIP1 and RIP3 are required for GX15-070-triggered cell death and suppression of long-term clonogenic survival downstream of autophagosome formation. GX15-070 suppresses RMS growth in vivo in a RIP1-dependent manner. Finally, we evaluated the antitumor activity of GX15-070 and the requirement of RIP1 in vivo using the chicken chorioallantoic membrane (CAM) model, an established preclinical tumor model. 32, 33 RMS cells were seeded on the CAM of chicken embryos and allowed to form tumors before treatment with GX15-070 was started. Importantly, treatment with GX15-070 significantly suppressed tumor growth of RMS in vivo (Figure 8 ). Of note, RIP1 knockdown significantly rescued this GX15-070-mediated suppression of tumor growth (Figure 8 ), indicating that RIP1 is required for the antitumor activity of GX15-070 in vivo.
Discussion
Although autophagy has previously been implicated in GX15-070-mediated cytotoxicity, the key question whether or not autophagy promotes or inhibits cell death in this context has been a subject of controversial discussion. Also, the biochemical events that link autophagy to cell death induction upon treatment with GX15-070 have so far remained elusive. Here, we identify GX15-070-stimulated assembly of the necrosome on autophagosomal membranes as a key event that connects the induction of autophagy to cell death via necroptosis. GX15-070 causes massive accumulation of autophagosomes and promotes the interaction of Atg5, a component of autophagosomal membranes, with key constituents of the necrosome, that is, FADD, RIP1 and RIP3 (Supplementary Figure S5) . This leads to the formation of a cytosolic cell death signaling complex that initiates necroptotic cell death. Several independent pieces of evidence support this conclusion.
First, GX15-070 triggers the assembly of large numbers of autophagosomes as demonstrated by massive conversion of LC3-I to LC3-II. Autophagic flux studies indicate that autophagy is predominately engaged by increased generation of autophagosomal membranes rather than disruption of the autophagic flux. GX15-070 has previously been shown to initiate autophagy by disrupting the interaction between Beclin1 and antiapoptotic Bcl-2 proteins, such as Mcl-1. 10, 11 Second, this engagement of autophagy is required for GX15-070-induced cell death, as genetic silencing of autophagy genes such as Atg5 or Atg7 inhibits GX15-070-triggered accumulation of autophagosomal membranes as well as cell death. Third, RIP1 is necessary for GX15-070-induced cell death, as both genetic and pharmacological inhibition of RIP1 by RIP1 knockdown or by the RIP1-specific inhibitor Nec-1 blocks GX15-070-induced cell death. Fourth, similar to RIP1, genetic silencing of RIP3 rescues the GX15-070-induced cell death and suppression of clonogenic survival. Both RIP1 and RIP3 mediate cell death downstream of autophagy induction, as their knockdown inhibits GX15-070-induced cell death but not autophagosome formation. Thus, by dissecting the different steps of the signaling cascade during GX15-070-triggered cell death via selective knockdown or pharmacological inhibition of individual signaling components, we provide genetic and biochemical evidence that GX15-070 induces necroptosis by promoting the assembly of the necrosome on autophagosomal membranes. By linking autophagy induction to necroptosis signaling, these findings provide new insights into the mechanisms of GX15-070-induced non-apoptotic cell death.
Our findings indicating that knockdown of either Atg5 or Atg7 severely impairs the GX15-070-induced formation of autophagosomal membranes are consistent with the requirement of these two autophagy genes for vesicle elongation and formation of autophagosomes.
14 Importantly, we demonstrate genetic evidence that autophagy represents a cell death rather than a survival mechanism upon treatment with GX15-070, as blockade of autophagy by silencing either Atg5 or Atg7 severely impairs GX15-070-triggered cytotoxicity.
GX15-070 has previously been described to induce autophagy in an Atg5- 9, 11 or Atg7-dependent manner. 17 However, the question whether or not autophagy represents a cell death or survival mechanism during GX15-070-mediated cytotoxicity has been controversially discussed. Although Atg5 was shown to be required for GX15-070-triggered cell death in some reports, thereby supporting a cytodestructive function of autophagy, 9, 11 Atg7 knockdown failed to protect against GX15-070-induced loss of clonogenicity or ultrastructural changes in another study. 17 Also, pharmacological inhibition of autophagy using the PI3K inhibitor 3-MA was described to either inhibit 10 or enhance GX15-070-induced cell death. 18 Together, these reports suggest that GX15-070 may trigger cell death via autophagy in a context-dependent manner.
Although autophagy is predominately known for its ability to maintain cell viability, it is increasingly appreciated that autophagy can exert dual functions, acting either as a survival or cell death mechanism. 16, 34 The pro-survival function of autophagy has been linked to its ability to suppress apoptosis as well as non-apoptotic forms of cell death, including necroptosis. [34] [35] [36] [37] Vice versa, there are a number of studies showing that autophagy leads to cell death via apoptotic or non-apoptotic routes. 16, 38 On mechanistic grounds, components of autophagosomal membranes have been linked to cell death signaling pathways, in particular to apoptosis. Using the yeast two-hybrid screening system, Atg5 was found to interact with the death domain of FADD, although Atg5 itself does not contain a bona fide death domain. 39 In this model of autophagic cell death following stimulation with IFNg, autophagy was shown to occur upstream of caspase activation, as the wide-spectrum caspase inhibitor zVAD blocked cell death but not autophagic vacuole formation. 39 Furthermore, preautophagosomal membranes containing Atg5-Atg12-Atg16L have been shown to recruit FADD and caspase-8 to form a cytosolic complex that promotes dimerization and activation of caspase-8 in proliferating T cells. 40 In this model, caspase-8 activation was reported to support the survival of proliferating T cells by cleaving RIP1, thereby shutting down necroptosis, 40 as RIP1-dependent necroptosis was unleashed in caspase-8-or FADD-deficient T cells, where this caspase-8-mediated negative control of necroptosis was missing. 40 Interestingly, an asymmetric distribution of Atg5-Atg12-Atg16L on the outer surface of the autophagosomal isolation membrane has been reported, 15 which could facilitate the interaction of Atg5-Atg12-Atg16L with cell death signaling proteins in the cytosol. Moreover, the sphingosine kinase inhibitor SPI-I and the proteasome inhibitor Bortezomib were described to promote self-association of caspase-8 and its autocatalytic processing on autophagosomal membranes in a Atg5-and p62-dependent manner. 41 In addition, the proteasome inhibitor MG132 has been shown to trigger oligomerization and activation of caspase-8 at intracellular membranes via the interaction of ubiquitinated caspase-8 with p62. 42 p62 is an autophagy receptor protein that binds on one side via its UBA domain to ubiquitin-tagged proteins and on the other side via its LIR domain to the autophagosomal membrane protein LC3-II. 43 As p62 was shown to bind to ubiquitinated caspase-8 to facilitate its oligomerization and activation in the cytosol, 44 p62 may serve as an additional link besides Atg5 between autophagosomal membranes and components of the apoptotic machinery. It is interesting to note that we did not detect caspase-8 recruitment to autophagosomal membranes upon treatment with GX15-070 despite expression of caspase-8 in RMS cells, suggesting that the interaction of caspase-8 with autophagosomes is regulated by additional factors.
In this context of autophagic, non-apoptotic cell death, our study is the first to show in the course of GX15-070-induced cell death that autophagy is linked to necroptosis signaling via the recruitment of the necrosome to autophagosomes. In addition, we demonstrate for the first time that RIP3 in addition to RIP1 is critically required for GX15-070-induced necroptosis. RIP1, but not RIP3, has previously been implicated in GX15-070-induced cell death in ALL cells, 10 although the underlying molecular events have so far remained elusive. Thus, together with previous reports, our findings support a model that autophagosomal membranes can engage cell death pathways via either the apoptotic or the necroptotic route, probably in a context-dependent manner. The decision which cell death program is engaged for the execution phase is likely controlled by several factors, for example, the availability and/or function of signaling proteins (e.g., caspase-8, FADD, RIP1, RIP3), the cell death stimulus or the cell type. Also, post-translational modifications may be involved, as intracellular aggregation of caspase-8 and its interaction with p62 has recently been correlated with its ubiquitination status. 42, 44 Our study has several important implications. First, we identify a molecular mechanism for GX15-070-induced nonapoptotic cell death by demonstrating that GX15-070 triggers necroptosis by promoting the assembly of the necrosome on autophagosomes. Beyond GX15-070, these findings provide, in a more general sense, new insights into the regulatory mechanisms of cell death by autophagy. A better understanding of the events that link autophagic signaling to cell death induction is especially important in order to exploit the autophagic machinery for cancer therapy.
In addition to these insights into the signal transduction pathways that are regulated by GX15-070 in cancer cells, our findings are relevant for the design of experimental therapies for RMS that aim at overcoming treatment resistance. As apoptosis is frequently impaired in RMS, for example, by overexpression of antiapoptotic Bcl-2 family proteins, 28 the activation of non-apoptotic cell death programs becomes more and more important as an alternative strategy, especially in apoptosis-resistant tumors. Thus, therapeutic induction of necroptosis may open new perspectives for the development of novel treatment approaches in cancers, including RMS.
Materials and Methods
Cell culture and chemicals. RMS cell lines were obtained from the American Type Culture Collection (Manassas, VA, USA) and maintained in RPMI 1640 (Life Technologies, Darmstadt, Germany), supplemented with 10% fetal calf serum (Biochrom, Berlin, Germany), 1 mM glutamine (Invitrogen, Karlsruhe, Germany), 1% penicillin/streptomycin (Invitrogen) and 25 mM HEPES (Biochrom). Enbrel was kindly provided by Pfizer (Berlin, Germany). zVAD.fmk was purchased from Bachem (Heidelberg, Germany), recombinant human TNFa from Biochrom, Nec-1 from Biomol (Hamburg, Germany) and all chemicals from Sigma (Deisenhofen, Germany) unless indicated otherwise.
RNA interference. For stable gene knockdown, lentiviral shRNA vectors targeting RIP1 sequence (5 0 -ccactagtctgacggataa-3 0 ) or a control sequence with no corresponding part in the human genome (5 0 -gatcatgtagatacgctca-3 0 ) were used as previously described. 45 Stable cell lines were produced by selection with 1 mg/ml puromycin (Sigma). For Atg5 and RIP3 knockdown, HEK293T producer cells were transfected with 7.5 mg pGIPZ-shRNAmir vector, 12.5 mg pCMV-dR8.91 and 1 mg pMD2.G using calcium phosphate transfection. All pGIPZ-shRNAmirvectors were purchased from Thermo Fisher Scientific (Waltham, MA, USA): nonsilencing control (shCtrl): RHS4346, shAtg5#1: 5 0 -TGAAAGAAGCTGATGCTTT-3 0 , shAtg5#2: 5 0 -GCTATATCAGGATGAGATA-3 0 , shRIP3#1: 5 0 -ACAACTACTTGAC-TATGCA-3 0 , and shRIP3#2: 5 0 -CAGAACTGTTTGTT AACGT-3 0 . The virus containing supernatant was collected after 48 h and filtered using a 45 mm filter. Cells were transduced by centrifugation at 1000 Â g for 1 h at room temperature in the presence of 8 mg/ml polybrene and selected with 1 mg/ml puromycin. For transient knockdown of Atg7, cells were seeded at 1 Â 10 5 /well in a six-well tissue culture plate and allowed to settle overnight. Cells were transfected with 150 pmol of each sequence of StealthTM RNAi (Invitrogen) against Atg7 (ATG7HSS116183) or non-targeting control siRNA (12935) (Invitrogen) using TransMessenger transfection (Qiagen, Hilden, Germany), which was replaced by complete medium after 3.5 h. Seventy-two hours after transfection, cells were reseeded in a 24-well tissue culture plate, allowed to settle overnight and treated with GX15-070. For transient knockdown of TNFR1 or Bcl-2, transfection mix was prepared by diluting 20 mM of each sequence of Silencer Select (Life Technologies) non-targeting control siRNA (4390843), Bcl-2 siRNA (s14265 and s14266) or TNFR1 siRNA (s1916 and s194310) in Opti-MEM (Life Technologies) and Lipofectamine RNAiMAX Transfection Reagent (Life Technologies) and incubated for 5 min. In all, 1.5 Â 10 5 /ml cells were seeded on top of transfection medium, allowed to settle overnight and treated with GX15-070.
Determination of apoptosis, cell viability and colony formation. Apoptosis was determined by fluorescence-activated cell-sorting (FACSCanto II, BD Biosciences, Heidelberg, Germany) analysis of DNA fragmentation of propidium iodide-stained nuclei as described previously. 46 Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay according to the manufacturer's instructions (Roche Diagnostics, Mannheim, Germany). For colony assay, cells were seeded as single cells (100 cells/well) in six-well plates for 24 h, treated for 48 h before medium was exchanged by fresh, drug-free medium and cells were cultured for additional 10 days before staining with crystal violet solution (0.75% crystal violet, 50% ethanol, 0.25% NaCl, 1.57% formaldehyde).
Western blot analysis. Western blot analysis was performed as described previously 46 using the following antibodies: mouse anti-caspase-8 (Enzo, Lörrach, Germany), mouse anti-Bcl-2, rabbit anti-Bcl-X L, mouse anti-Bax, mouse anti-Bak, mouse anti-RIP1, mouse anti-FADD (BD Transduction Laboratories, Heidelberg, Germany), rabbit anti-Atg5, rabbit anti-Bid, rabbit anti-Bim, rabbit anti-caspase-3, mouse anti-caspase-9 (Cell Signaling, Beverly, MA, USA), rabbit anti-Atg7 (AbCam, Cambridge, UK), rabbit anti-LC3 (Thermo Fisher Scientific Inc., Rockford, IL, USA), mouse anti-Noxa (Alexis, Grünberg, Germany), rabbit antiMcl-1 (Stressgen, Aachen, Germany), mouse anti-Bcl-2 (Invitrogen), mouse anti-TNFR1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and rabbit anti-RIP3 (Imgenex, San Diego, CA, USA). Mouse anti-GAPDH (HyTest, Turku, Finland) or mouse anti-b-actin (Sigma) were used as loading controls. Goat anti-mouse IgG, GX15-070 triggers necroptosis via autophagy F Basit et al
